NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

I heard it more like longfellow did. She was talking about the crossover time, and said [22:30] :

Because of that we actually added a crossover arm at progression. At the time it seemed like this was fine. But it actually subsequently muddied the data analysis afterwards. And why that happened was this concept of pseudoprogression that I mentioned earlier.

Perhaps you are thinking of a minute later following the slide on McD., RANO, iRANO later when she used the word assigned [24:13] :

But at the time the trial was written that wasn't the standard. The standard was you sent the scan to the radiologist, and the radiologist is blinded and that was when people got assigned to either progression or non progression

So in the use the term was not the randomization assignment, but the PFS determination.

Longfellow: I have no issue with the use of "muddy" vs confound. But they mean exactly the same say in this context. In cancer trials where the patient will often use various other follow up treatments after failure, OS is invariably somewhat confounded. Just is, but is not the end of the world.